Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.51 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.43 |
| ▸ | TPH1 | P17752 | 5/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5124921 | 0.90 | HDAC1 (0.48) | HDAC8TPH1DPP7HDAC1HDAC6 | |
| SCHEMBL4597791 | 0.90 | HDAC8 (0.49) | HDAC8SMPD1HDAC1 | |
| SCHEMBL4598222 | 0.90 | HDAC8 (0.49) | HDAC8SMPD1HDAC1HDAC6DPP4 | |
| SCHEMBL4597882 | 0.82 | HDAC8 (0.64) | HDAC8SMPD1TPH1HDAC1HDAC6 | |
| SCHEMBL5121832 | 0.80 | MMP8 (0.47) | HDAC8TPH1HDAC1HDAC6DPP4 | |
| SCHEMBL4598564 | 0.79 | HDAC8 (0.55) | HDAC8SMPD1HDAC1HDAC6 | |
| SCHEMBL4597924 | 0.74 | HDAC8 (0.53) | HDAC8HDAC1HDAC6 | |
| SCHEMBL4597495 | 0.73 | HDAC6 (0.44) | HDAC8HDAC1HDAC6 | |
| SCHEMBL4828572 | 0.72 | HDAC6 (0.49) | HDAC8TPH1HDAC1HDAC6 | |
| SCHEMBL4598073 | 0.72 | SLC7A5 (0.51) | TPH1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200521-A1 | Novel hydroxamic acid containing amino acid derivatives | BEXEL PHARMACEUTICALS. INC. | 2008-08-21 | — | — | US | claimed |
| EP-1906731-A2 | NOVEL HYDROXAMIC ACID-CONTAINING AMINO ACID DERIVATIVES | Bexel Pharmaceuticals Inc (US) | 2008-04-09 | — | — | EP | claimed |
| WO-2007005603-A2 | NOVEL HYDROXAMIC ACID-CONTAINING AMINO ACID DERIVATIVES | BEXEL PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | WO | claimed |
| US-20070004776-A1 | Novel hydroxamic acid-containing amino acid derivatives | BEXEL PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200521-A1 | Novel hydroxamic acid containing amino acid derivatives | HGFAC, HCAR2, BCAT1 | HDAC8 154/4885SMPD1 2769/4885TPH1 583/4885 |
| US-20070004776-A1 | Novel hydroxamic acid-containing amino acid derivatives | HGFAC, HCAR2, BCAT1 | HDAC8 176/4885SMPD1 2995/4885TPH1 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.